Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Prurigo Nodularis
In brief
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
Key facts
- Study ID
- NCT06779136
- Run by
- Shanghai Mabgeek Biotech.Co.Ltd
- People needed
- 160
- Starts
- 2025-02-26
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2025-04-18
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Peking University People's Hospital, Beijing, — Beijing, Bejing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.